pharmaphorum
JANUARY 5, 2022
The year 2020 ended on a note of hope, with the 8th December vaccination of 91-year-old Margaret Keenan, the world’s first person to receive a COVID-19 vaccine outside clinical trials. The next phase of the Covid-19 – from vaccines to treatments. New COVID-19 treatments will also be available in 2022, but they are not a panacea.
Pharmacy Friday Pearls
MARCH 4, 2022
18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 29, 2022
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. On average, launches of 2020’s cohorts both underperformed. The scope of the problem. Launches, therefore, were happening.
ALiEM - Pharm Pearls
OCTOBER 30, 2024
Bupe Allergy Buprenorphine induction has been the mainstay of emergency department treatment of opioid use disorder for more than a decade [11, 12]. Of note, screening is often required for insurance approval for substance use treatment. Our experience: Traditionally, ED physicians do not like ordering urine drug screens (UDS).
RX Note
JULY 3, 2023
. ° Nil © Complete ABG Arterial blood gases abx Antibiotics ACE Angiotensin converting enzyme ACS Acute coronary syndrome ADHD Attention deficit hyperactivity disorder ADME Absorption, distribution, metabolism or excretion ADR Adverse drug reaction AEBA Acute exacerbation of bronchial asthma AF Atrial fibrillation AGE Acute gastroenteritis AIDS Acquired (..)
PharmaShots
APRIL 25, 2023
This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. ARO-AAT and ARO-APOC3 are among the highest-phase products developing under Arrowhead’s pipeline for the treatment of liver diseases. R&D Expenditure: $85.1M R&D Expenditure: $437.9M
RX Note
FEBRUARY 23, 2023
Soft Contact Lenses - A basic overview Red Eye - Discussion on few possible conditions Styes - Warm compresses are the mainstay of treatment Eye Floaters - It is not often treated, except in severe cases.
Expert insights. Personalized for you.
98 
Let's personalize your content